Vancamelbeke, M., Vermeire, S. The intestinal barrier: a fundamental role in health and disease. Rev Gastroenterol Hepatol 2017; 11(9): 821: 834.
Luissint, A.-C., et al. Inflammation and the intestinal barrier: leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair. Gastroenterology 2016; 151: 616–632.
Pascual, S.; Martínez, J.; Pérez-Mateo, M. La barrera intestinal: trastornos funcionales en enfermedades digestivas y extradigestivas. Gastroenterol Hepatol 2001; 24: 256–267.
Bischoff, S.C., et cols. Intestinal permeability: a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189.
Martini, E., et cols. The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 2017; 4: 33–46.
Camilleri, M., et cols. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012; 24(6): 503–512.
The Monash University Low FODMAP Diet. Disponible en: http://www.med.monash.edu/ cecs/gastro/fodmap/description.html
World J Gastroenterol. 2015 Jan 14; 21(2): 600-608. doi: 10.3748/wjg.v21.i2.600. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects http://www.med.monash.edu/cecs/ gastro/fodmap/
Rao, S.S.C.; Yu, S.; Fedewa, A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015; 41(12): 1256–1270.
Halmos, E.P.; Power, V.A.; Shepherd, S.J.; Gibson, P.R.; Muir, J.G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. J Gastro. 2014 Jan; 146(1): 67–75.e5.
Zugasti Murillo, A.; Estremera Arévalo, F.; Petrina Jáuregui, E. Dieta pobre en FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) en el síndrome de intestino irritable: indicación y forma de elaboración. Rev Endocrinología y Nutrición 2016; 63(3): 132–138.
Harvard Health Publishing. Try a FODMAPs diet to manage irritable bowel syndrome. Disponible en: http://www.health.harvard.edu/ diet-and-weight-loss/a-new-diet-to-manage-irritable-bowel-syndrome
Halmos, E.P.; Christophersen, C.T.; Bird, A.R., et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015; 64: 93–100.
Mansueto, P.; Seidita, A.; D’Alcamo, A et al. Role of FODMAPs in Patients With Irritable Bowel Syndrome A Review. Nutr Clin Pract. 2015.
Böhn, L.; Störsrud, S.; Liljebo, T., et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015; 149(6): 1399–1407.
Martin, L.; Van Vuuren, C.; Seamark, L., et al. Long term effectiveness of short chain fermentable carbohydrate (FODMAP) restriction in patients with irritable bowel syndrome. Gut. 2015; 64(1): A51-A52.
Iacovou, M.; Tan, V.; Muir, J.G.; Gibson, P.R. The Low FODMAP Diet and Its Application in East and Southeast Asia. J Neurogastroenterol Motil. 2015; 21(4): 459–470.
Yoon, S.R.; Lee, J.H.; Lee, J.H., et al. Low-FODMAP formula improves diarrhea and nutritional status in hospitalized patients receiving enteral nutrition: a randomized, multicenter, double-blind clinical trial. Nutrition Journal. 2015; 14(1): 1-1.
Gibson, P.R.; Muir, J.G.; Newnham, E.D. Other dietary confounders: FODMAPS et al. Dig Dis. 2015; 33(2): 269–276.
Hayes, P.A., et cols. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol 2014; 10(3): 164–174.
Lee, B.J.; Bak, Y.T. Irritable bowel syndrome, gut microbiota and probiotis. J Neurogastroenterol Motil 2011; 17(3): 252–266.
Mearin, F. Diagnóstico del síndrome del intestino irritable: criterios clínicos y biomarcadores. Elsevier: 2016; (8): 121–133.
Mearin, F., et cols. Guía de práctica clínica del síndrome del intestino irritable con estreñimiento y estreñimiento funcional en adultos: tratamiento (Parte 2 de 2). Rev Atención Primaria 2017; 49(3): 177–194.
Zugasti Murillo, A. Intolerancia alimentaria. Rev Endocrinología y Nutrición 2009; 56(5): 241–250.
Fedewa, A.; Rao, S.S. Dietary fructose intolerance, fructan intolerance and FODMAPs. Curr Gastroenterol Rep, v. 16, n.° 1, 370, Jan 2014. ISSN 1522-8037.
Shepherd, S.J.; Gibson, P.R. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc, v. 106, n.° 10, 1631-1639, Oct 2006. ISSN 0002-8223 (Print) 0002-8223.
Skoog, S.M.; Bharucha, A.E. Dietary fructose and gastrointestinal symptoms: a review. Am J Gastroenterol, v. 99, n.° 10, 2046-2050, Oct 2004. ISSN 0002-9270 (Print) 0002-9270.
Varney, J., et al. FODMAPs: food composition, defining cutoff values and international application. J Gastroenterol Hepatol, v. 32, Suppl 1, 53-61, Mar 2017. ISSN 0815-9319.
Jianqin, S.; Leiming, X.; Lu, X.; Yelland, G.W.; Ni, J.; Clarke, A.J. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows’ milk. Nutr J. 2016 Apr 2; 15: 35.
Bartley, J.; McGlashan, S.R. Does milk increase mucus production? Med Hypotheses. 2010 Apr; 74(4): 732–734.
Trivedi, M.S.; Shah, J.S.; Al-Mughairy, S.; Hodgson, N.W.; Simms, B.; Trooskens, G.A.; Van Criekinge, W.; Deth, R.C. Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J Nutr Biochem. 2014 Oct; 25(10): 1011.
Brooke-Taylor, S.; Dwyer, K.; Woodford, K.; Kost, N. Systematic Review of the Gastrointestinal Effects of A1 Compared with A2 ß-Casein. Adv Nutr 2017; 8(5): 739–748.
Zugasti Murillo, A. Intolerancia alimentaria. Rev Endocrinología y Nutrición 2009; 56(5): 241–250.
Sensibilidad al gluten no celiaca. FACE 2016. Disponible en: https://celiacos.org/sensibilidad-al-gluten-no-celiaca/
Molina-Infante, J.; Santolaria, S.; Montoro, M.; Esteve, M.; Fernández-Bañares, F. Sensibilidad al gluten no celiaca: una revisión crítica de la evidencia actual. Rev Gatroent y Hepatol 2014; 37(6): 362–371.
Biesiekierski, J.R. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145(2): 320–328.
Reig-Otero, Y.; Mañes, J.; Manyes i Font, L. Sensibilidad al gluten no celiaca (SGNC): manejo nutricional de la enfermedad. Nutr Clin Diet Hosp 2017; 37(1): 171–182.
Miazga, A.; Osiński, M.; Cichy, W.; Żaba, R. Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. Adv Med Sci 2015; 60(1): 118–124.
Chedid, V., et cols. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med 2014; 3(3): 16–24.
Quigley, E.M. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol 2014; 30(2): 141–146.
Gibson, P.R.; Shepherd, S.J. Evidence based dietary management of functional gastrointestinal symptoms: The FODMAP approach. Journal of gastroenterology and hepatology 2012; 25(2): 252–258.
Rahimi, R.; Nikfar, S.; Abdollahi, M. Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol 2013; 19(34): 5738–5749.
Lauritano, E.C. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103(8): 2031-2035.
Zhong, C.; Qu, C.; Wang, B.; Liang, S.; Zeng, B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol 2017; 51(4): 300–311.
Bento, C., et cols. Mammalian Autophagy, how does it work? Annual Review of Biochemistry 2016; 85: 685-713.93.
Horne Benjamín, D., et cols. Health ffects of intermittent fasting: hormesis or harm? A systematic review. The American Journal of Clinical Nutrition 2015; 102: 464–470.
Pimentel, M., et cols. Lower Frequency of MMC Is Found in IBS Subjects with Abnormal Lactulose Breath Test, Suggesting Bacterial Overgrowth. Dig Dis Sci 2002; 47: 2639.
Choi, J. The parasitophorous vacuole membrane of Toxoplasma gondii is targeted for disruption by ubiquitin-like conjugation systems of autophagy. Immunity 2014; 40(6): 924–935.
Sciarretta, S.; Boppana, V.S.; Umapathi, M.; Frati, G.; Sadoshima, J. Boosting autophagy in the diabetic heart: a translational perspective. Cardiovasc Diagn Ther 2015; 5(5): 394–402.
Horne, B.D. Randomized cross-over trial of short-term water-only fasting: metabolic and cardiovascular consequences. Nutr Metab Cardiovasc Dis 2013; 23(11): 1050–1057.
Varady, K.A. Intermittent versus daily calorie restriction: which diet regimen is more effective for weight loss? Obes Rev 2011; 12(7): 593–601.
Varady, K.A.; Bhutani, S.; Church, E.C.; Klempel, M.C. Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults. Am J Clin Nutr 2009; 90(5): 1138–1143.
Aksungar, F.B.; Topkaya, A.E.; Akyildiz, M. Interleukin-6, C-reactive protein and biochemical parameters during prolonged intermittent fasting. Ann Nutr Metab 2007; 51(1): 88–95.
Teng, N.I., et cols. Efficacy of fasting calorie restriction on quality of life among aging men. Physiol Behav 2011; 104(5): 1059–1064.
Ohkawara, K.; Cornier, M.A.; Kohrt, W.M.; Melanson, E.L. Effects of increased meal frequency on fat oxidation and perceived hunger. Rev Obesity 2013; 21(2): 336–343.
Endocrin Society 2018. Consuming low-calorie sweeteners may predispose overweight individuals to diabetes. Disponible en: https://www.endocrine. org/news-and-advocacy/news-room/2018/consuming-lowcalorie-sweeteners-may-predispose-overweight-individuals-to-diabetes